Vol. I · Est. 2025 · Houston, TX
Peptide Atlas
The Complete Map of Peptide Research
⚲
PCAC Result
BPC-157Rec. 503A
TB-500Rec. 503A
KPVRec. 503A
MOTS-cRec. 503A
SemaxRec. 503A
EpitalonRec. 503A
DSIPDeclined
PCAC Jul 2026: 6 of 7 recommended →
Source · Lone Star →
Regulatory Update — July 2026

The FDA panel just backed 6 of 7 peptides.

On July 23–24, 2026, the FDA's compounding advisory committee recommended BPC-157, TB-500, KPV, MOTS-c, Semax, and Epitalon for the 503A list — a path back toward legal compounding. Only DSIP was turned down. Here is what it actually means.

See the Full Result → Browse the Library
Educational reference only. Not medical advice. Not instruction for human use. Peptide Atlas is created by Lone Star Peptide Co., Houston TX. Full disclosure.
Regulatory Result
PCAC recommended 6 of 7 peptides for the 503A list
Advisory vote, July 23–24, 2026. BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon recommended; DSIP declined. FDA rulemaking still to follow.
See the Breakdown →
Reference Index
Dose Reference Index
Commonly discussed research amounts for 15 compounds, with divergence indicators and live regulatory status. The only free index of its kind.
View the Index →
Transparency Directory
Vendor Directory
Compare research peptide suppliers by COA documentation, third-party testing, domestic fulfillment, and transparency scores. Sponsored listings disclosed.
Compare Vendors →
Regulatory Tracker
Regulatory Status Tracker
The July 2026 PCAC result, compound by compound, plus what still has to happen at the FDA before anything is final. Explained plainly.
View Tracker →
Compound Comparison
BPC-157 vs TB-500
Side-by-side comparison across mechanism, evidence level, research applications, regulatory status, and community divergence.
Read Comparison →
Regulatory Analysis
What the PCAC Vote Means for BPC-157
Plain-English walkthrough of the July 2026 recommendation: what changes for compounding pharmacies, what doesn't for RUO suppliers, the FDA timeline still ahead, and what to watch.
Read Analysis →
Where to Source
The peptides the FDA panel just backed — source them here

BPC-157, TB-500, KPV, MOTS-c and more were just recommended for the 503A list. Lone Star Peptide Co. supplies research-grade material — batch-specific COAs, third-party testing, and same-day shipping from Houston, TX.

Peptide Atlas is created by Lone Star Peptide Co. — a disclosed placement. Full disclosure.
Visit Lone Star Peptide Co. →
Free Research Digest
The Peptide Research Digest
Regulatory updates, new compound coverage, and vendor transparency changes. No sales pitch.
No spam · Unsubscribe any time